fbpx
Your browser is out-of-date!

Update your browser to view this website correctly. Update my browser now

×

View All News
May 27, 2021

Scout Bio to Present at Stifel 2021 Virtual Jaws & Paws Conference

PHILADELPHIA, May 27, 2021 (GLOBE NEWSWIRE) — Scout Bio today announced that Mark Heffernan, Chief Executive Officer, will present at the upcoming Stifel 2021 Virtual Jaws & Paws Conference on Thursday, June 3, 2021 at 3:00 p.m. ET.

About Scout Bio
Scout Bio is a biotechnology company revolutionizing pet medicine by delivering a deep pipeline of one-time gene therapies for major chronic pet health conditions. Scout Bio’s therapeutics are designed to induce long-term expression of therapeutic proteins in pet patients using AAV vector technology. Scout Bio has a research and development collaboration with the University of Pennsylvania’s Gene Therapy Program, a leader in the field of genetic medicine research. Scout Bio is a private company headquartered in Philadelphia, Pennsylvania. For more information, see www.scoutbio.co

For further information, please contact:

Investors:

Sarah McCabe
Stern Investor Relations, Inc.
212.362.1200
sarah.mccabe@sternir.com

Media:

Fran Gaconnier
Scout Bio
214.417.4142
fran.gaconnier@scoutbio.co

  • News

Scout Bio Appoints Life Sciences Executive Aaron Schacht to Board of Directors

Brings experience in managing global innovation portfolios and business development to Scout Bio Executive leadership experience across both animal and human health PHILADELPHIA, February 18, 2022 – Scout Bio,…

  • News

Scout Bio to Present at Upcoming Animal Health Conferences

PHILADELPHIA, February 15, 2022 – Scout Bio, a biotechnology company developing therapeutic proteins and one-time AAV gene therapies for major chronic pet health conditions, today announced that it will…

  • News

Scout Bio Expands Gene Therapy Collaboration with the University of Pennsylvania Via Next-Generation Vector Technologies

Partnership agreement includes exclusive rights in animal health to novel viral vector capsid and expands additional option rights to novel capsids Next-generation novel adeno-associated viral (AAV) vector capsid promises…